Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients.
BACKGROUND
A few recent studies have suggested that other sexually transmitted infections may increase the likelihood of a human papillomavirus (HPV) infection progressing to high-grade cervical neoplasia and cancer.


OBJECTIVE
The goal was to assess whether exposures to Chlamydia trachomatis, human T-cell lymphotrophic virus type 1 (HTLV-I), and/or human simplex virus type 2 (HSV-2) are greater in colposcopy patients with cervical intraepithelial neoplasia grade 3 or cancer (CIN3+) than in patients with low-grade cervical neoplasia (CIN1).


METHODS
Sequential patients (n=447) attending a colposcopy clinic in Kingston, Jamaica, a country with high cervical cancer rates and high HTLV-I prevalence, were tested for (1) HPV DNA by L1 consensus primer (MY09/11) polymerase chain reaction assays, (2) C trachomatis DNA by ligase chain reaction, (3) C trachomatis antibodies by both microimmunofluorescence and a peptide (VS4) enzyme linked immunosorbent assay (ELISA), (4) HTLV-I antibodies by ELISA confirmed by western blotting, and (5) HSV-2 antibodies by a recombinant HSV-2-specific ELISA. Odds ratios and 95% confidence intervals were estimated with use of multinomial logistic regression models.


RESULTS
HPV DNA detection was associated with grade of cervical neoplasia but other evaluated sexually transmitted infections were not.


CONCLUSIONS
HTLV-I, C trachomatis, and/or HSV-2 were not associated with severity of cervical neoplasia in Jamaican women.
Castle
Philip E
PE
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA. pc95p@nih.gov
Escoffery
Carlos
C
Schachter
Julius
J
Rattray
Carole
C
Schiffman
Mark
M
Moncada
Jeanne
J
Sugai
Karlyn
K
Brown
Claudette
C
Cranston
Beverly
B
Hanchard
Barrie
B
Palefsky
Joel M
JM
Burk
Robert D
RD
Hutchinson
Martha L
ML
Strickler
Howard D
HD
D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis; D000914:Antibodies, Viral / Q000032:analysis; D015153:Blotting, Western; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D003127:Colposcopy; D004269:DNA, Bacterial / Q000032:analysis; D004279:DNA, Viral / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D018258:Herpesvirus 2, Human / Q000302:isolation & purification; D015368:Human T-lymphotropic virus 1 / Q000302:isolation & purification; D006801:Humans; D007563:Jamaica / Q000453:epidemiology; D008875:Middle Aged; D016017:Odds Ratio; D027383:Papillomaviridae / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction; D012307:Risk Factors; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000382:microbiology* / Q000473:pathology / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology* / Q000382:microbiology* / Q000473:pathology / Q000821:virology
D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D004269:DNA, Bacterial; D004279:DNA, Viral